TScan Therapeutics (TCRX) Accumulated Depreciation & Amortization (2020 - 2024)
Historic Accumulated Depreciation & Amortization for TScan Therapeutics (TCRX) over the last 5 years, with Q4 2024 value amounting to $4.1 million.
- TScan Therapeutics' Accumulated Depreciation & Amortization fell 2407.41% to $4.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year decrease of 2407.41%. This contributed to the annual value of $4.1 million for FY2024, which is 2407.41% down from last year.
- Per TScan Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $4.1 million for Q4 2024, which was down 2407.41% from $5.4 million recorded in Q4 2023.
- TScan Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $5.4 million for Q4 2023, and its period low was $1.2 million during Q4 2020.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $4.1 million (2024), whereas its average is $3.8 million.
- As far as peak fluctuations go, TScan Therapeutics' Accumulated Depreciation & Amortization soared by 17500.0% in 2021, and later crashed by 2407.41% in 2024.
- TScan Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $1.2 million in 2020, then skyrocketed by 175.0% to $3.3 million in 2021, then skyrocketed by 54.55% to $5.1 million in 2022, then increased by 5.88% to $5.4 million in 2023, then decreased by 24.07% to $4.1 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $4.1 million for Q4 2024, versus $5.4 million for Q4 2023 and $5.1 million for Q4 2022.